Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.
Seventy-four post-menopausal women with metastatic breast cancer were treated with a combination hormonal regimen consisting of tamoxifen, aminoglutethimide danazol and medroxyprogesterone acetate (POND). 72% of the patients had received no previous treatment. The overall response rate (complete and partial remission) was 43.5% with a median response duration of 19 months and a median survival of 27 months. The most common sites of response were in regional nodes and local chest wall disease. The major side-effects were those expected from the individual agents: nausea, lethargy, rash and oedema.
Hardy
J R
JR
Department of Medicine, Royal Marsden Hospital, Surrey, U.K.
Powles
T J
TJ
Judson
I R
IR
Sinnett
H D
HD
Ashley
S E
SE
Coombes
R C
RC
Ellin
C L
CL
D000368:Aged; D000369:Aged, 80 and over; D000616:Aminoglutethimide / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003613:Danazol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013629:Tamoxifen / Q000008:administration & dosage
D013629:Tamoxifen; D000616:Aminoglutethimide; D008525:Medroxyprogesterone; D003613:Danazol